Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;47(3):552-573.
doi: 10.1007/s11064-021-03488-7. Epub 2021 Nov 20.

Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders

Affiliations
Review

Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders

Thuy Trang Nguyen et al. Neurochem Res. 2022 Mar.

Abstract

Neurodegenerative disorders are distinguished by the gradual deterioration of the nervous system's structure and function due to oxidative stress, mitochondrial dysfunction, protein misfolding, excitotoxicity, and neuroinflammation. Among these NDs, Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis characterized an increasing dysfunction and loss of neuronal structure leading to neuronal cell death. Although there is currently no drug to totally reverse the effects of NDs, such novel formulations and administration routes are developed for better management and nose-to-brain delivery is one of delivery for treating NDs. This review aimed to highlight advances in research on various lipid based nanocarriers such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and cubosomes which are reported to treat and alleviate the symptoms of NDs via nose-to-brain route. The challenges during clinical translation of lipid nanocarriers from bench to bed side is also discussed.

Keywords: Brain targeting; Intranasal delivery; Lipid nanocarriers; Neurodegenerative diseases; Nose-to-brain.

PubMed Disclaimer

References

    1. Van Giau V, An SSA, Bagyinszky E, Kim S (2015) Gene panels and primers for next generation sequencing studies on neurodegenerative disorders. Mol Cell Toxicol 11(2):89–143 - DOI
    1. TT Nguyen, TTD Nguyen, TKO Nguyen, TK Vo, VG Vo (2021) Advances in developing therapeutic strategies for Alzheimer’s disease. Biomed Pharmacoth 139: 111623.
    1. Jankovic J, Aguilar LG (2008) Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat 4(4):743–757 - PubMed - PMC - DOI
    1. Bertram L, Tanzi RE (2005) The genetic epidemiology of neurodegenerative disease. J Clin Invest 115(6):1449–1457 - PubMed - PMC - DOI
    1. Tajes M, Ramos-Fernández E, Weng-Jiang X, Bosch-Morató M, Guivernau B, Eraso-Pichot A, Salvador B, Fernàndez-Busquets X, Roquer J, Muñoz FJ (2014) The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol 31(5):152–167 - PubMed - DOI

LinkOut - more resources